About Us / History
Facts
| 2010 | FDA grants approval of ella® for emergency contraception |
|---|---|
| 2009 | Erin Gainer, former Executive Director of R&D, appointed CEO. André Ulmann, founder, becomes Chairman of the Supervisory Board. British and Italian and Spanish subsidiaries established in London, Roma and Madrid respectively. HRA Pharma granted Community Marketing Authorization for ellaOne® (ulipristal acetate) in the EU. |
| 2008 | German subsidiary, HRA Pharma Deutschland GmbH, established in Bochum. MA application for ellaOne® submitted to the EMEA. |
| 2007 | Licensing agreement with Swiss company PregLem to develop and commercialize ulipristal acetate for benign gynecological disorders. |
| 2006 | Launch of Mona Lisa line of copper contraceptive intra-uterine devices (IUDs) in France. Creation and launch of "Mona Lisa Afrique" program to provide training, education and IUDs to health care personnel free of charge in several West African countries. Collaborative research and development agreement with the US National Institute of Child Health and Human Development for the development of HRA 052015 (Mifedren®) for Cushing's syndrome secondary to ectopic ACTH secretion. Start of Phase III program of ella® /ellaOne® (ulipristal acetate), a new generation emergency contraceptive, in clinics affiliated with the Planned Parenthood Federation of America as well as NHS family planning clinics in the UK. |
| 2005 | Launch of a new dosage form of NorLevo® (1.5 mg single-dose administration). Acquisition of Celogos, a biotechnology company focused on cell therapy. |
| 2004 | Lysodren launched in 27 countries throughout Europe. To coincide with this launch, HRA Pharma also launches Lysosafe, a therapeutic monitoring assay service designed to help physicians to optimize Lysodren® prescription. Start of a collaborative project with the Population Council to develop HRA Pharma's ulipristal acetate for innovative non-estrogenic continuous contraception via novel, local delivery systems. Collaboration with the Department of Obstetrics and Gynecology at the Kobe University Graduate School of Medicine on the mechanism of action of ulipristal acetate for the treatment of uterine fibroids. |
| 2003 | |
| 2002 | NorLevo® approved for anonymous and free-of-charge dispensation to women under the age of 18 in France. Lysodren®, indicated for the symptomatic treatment of advanced adrenal cortical carcinoma, granted orphan drug status in Europe. Partnership with the Collaborative group for Adrenocortical Carcinoma Therapy to support the First International Randomized trial in Metastatic Adrenocortical Cancer Treatment (FIRM-ACT) study, the largest trial ever performed on this rare disease. |
| 2001 | Collaborative research and development agreement with the US National Institute of Child Health and Human Development for the clinical development of the candidate CDB-2914 (ulipristal acetate) for various reproductive health indications. |
| 2000 | NorLevo® approved for sale throughout Europe. HRA Pharma licenses-in CDB 2914 (ulipristal acetate). |
| 1999 | Launch in France of the company's first product, NorLevo®, the first emergency contraceptive based entirely on levonorgestrel, a synthetic progestin. NorLevo® is granted non-prescription status in France. |
| 1996 | HRA Pharma is established by Dr André Ulmann. |